Transcode Therapeutics CFO Thomas Fitzgerald Receives Award of 185,000 Options

What Happened

• Thomas A. Fitzgerald, Chief Financial Officer of Transcode Therapeutics, was granted a derivative award on 2026-09-09 covering 185,000 shares. The transaction is reported as an acquisition (code A) at $0.00 (derivative), indicating a grant of option-like rights rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-09-09; Form 4 filed: 2026-09-11 (filed within the normal 2-business-day window).
• Amount: 185,000 shares reported as a derivative award; transaction price reported as $0.00.
• Vesting: Per the filing footnote, the shares underlying this option vest and become exercisable in twelve (12) equal monthly installments following the grant date.
• Shares owned after transaction: Not specified in the supplied filing excerpt.
• No 10b5-1 plan, tax‑withholding, or late-filing flags are noted in the provided information.

Context

• This is a compensation grant (derivative award/options) rather than an immediate purchase or sale. The award vests over a year, so it does not represent an immediate change in market exposure and does not indicate an immediate sale of shares.